Affordable Access

Access to the full text

Persistent variations of blood DNA methylation associated with treatment exposures and risk for cardiometabolic outcomes in long-term survivors of childhood cancer in the St. Jude Lifetime Cohort

Authors
  • Song, Nan1, 2
  • Hsu, Chia-Wei3
  • Pan, Haitao3
  • Zheng, Yinan4
  • Hou, Lifang4
  • Sim, Jin-ah1
  • Li, Zhenghong1
  • Mulder, Heather3
  • Easton, John3
  • Walker, Emily3
  • Neale, Geoffrey3
  • Wilson, Carmen L.1
  • Ness, Kirsten K.1
  • Krull, Kevin R.1
  • Srivastava, Deo Kumar3
  • Yasui, Yutaka1
  • Zhang, Jinghui3
  • Hudson, Melissa M.1, 3
  • Robison, Leslie L.1
  • Huang, I-Chan1
  • And 1 more
  • 1 St. Jude Children’s Research Hospital, 262 Danny Thomas Place, MS 735, Memphis, TN, 38105, USA , Memphis (United States)
  • 2 Chungbuk National University, Cheongju, Korea , Cheongju (South Korea)
  • 3 St. Jude Children’s Research Hospital, Memphis, TN, USA , Memphis (United States)
  • 4 Northwestern University, Chicago, IL, USA , Chicago (United States)
Type
Published Article
Journal
Genome Medicine
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Apr 06, 2021
Volume
13
Issue
1
Identifiers
DOI: 10.1186/s13073-021-00875-1
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundIt is well-established that cancer treatment substantially increases the risk of long-term adverse health outcomes among childhood cancer survivors. However, there is limited research on the underlying mechanisms. To elucidate the pathophysiology and a possible causal pathway from treatment exposures to cardiometabolic conditions, we conducted epigenome-wide association studies (EWAS) to identify the DNA methylation (DNAm) sites associated with cancer treatment exposures and examined whether treatment-associated DNAm sites mediate associations between specific treatments and cardiometabolic conditions.MethodsWe included 2052 survivors (median age 33.7 years) of European ancestry from the St. Jude Lifetime Cohort Study, a retrospective hospital-based study with prospective clinical follow-up. Cumulative doses of chemotherapy and region-specific radiation were abstracted from medical records. Seven cardiometabolic conditions were clinically assessed. DNAm profile was measured using MethylationEPIC BeadChip with blood-derived DNA.ResultsBy performing multiple treatment-specific EWAS, we identified 935 5′-cytosine-phosphate-guanine-3′ (CpG) sites mapped to 538 genes/regions associated with one or more cancer treatments at the epigenome-wide significance level (p < 9 × 10−8). Among the treatment-associated CpGs, 8 were associated with obesity, 63 with hypercholesterolemia, and 17 with hypertriglyceridemia (false discovery rate-adjusted p < 0.05). We observed substantial mediation by methylation at four independent CpGs (cg06963130, cg21922478, cg22976567, cg07403981) for the association between abdominal field radiotherapy (abdominal-RT) and risk of hypercholesterolemia (70.3%) and by methylation at three CpGs (cg19634849, cg13552692, cg09853238) for the association between abdominal-RT and hypertriglyceridemia (54.6%). In addition, three CpGs (cg26572901, cg12715065, cg21163477) partially mediated the association between brain-RT and obesity with a 32.9% mediation effect, and two CpGs mediated the association between corticosteroids and obesity (cg22351187, 14.2%) and between brain-RT and hypertriglyceridemia (cg13360224, 10.5%). Notably, several mediator CpGs reside in the proximity of well-established dyslipidemia genes: cg21922478 (ITGA1) and cg22976567 (LMNA).ConclusionsIn childhood cancer survivors, cancer treatment exposures are associated with DNAm patterns present decades following the exposure. Treatment-associated DNAm sites may mediate the causal pathway from specific treatment exposures to certain cardiometabolic conditions, suggesting the utility of DNAm sites as risk predictors and potential mechanistic targets for future intervention studies.

Report this publication

Statistics

Seen <100 times